To our knowledge, there are very few studies investigating the relationship between the ratio of CD8 + T cells in the tumour stroma and the achievement of pCR induced by neoadjuvant therapy in patients with HER2 + breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.